AI Software for Brain MRI Gets Expanded FDA Clearance for Multiple Sclerosis Assessment
Through AI technology, Neurophet AQUA now provides multiple sclerosis (MS) analysis with a combination of lesion quantification and enhanced segmentation of T2-FLAIR MRI.
The Food and Drug Administration (FDA) has granted expanded 510(k) clearance for multiple sclerosis (MS) assessment with the magnetic resonance imaging (MRI)-based artificial intelligence (AI) software Neurophet AQUA.
Previously FDA-cleared for assessment of brain atrophy on MRI, Neurophet AQUA offers advanced analysis of MS and white matter hyperintensities based off of T2-weighted fluid-attention inversion recovery (FLAIR) MRI, according to Neurophet, the developer of Neurophet AQUA.
Based off brain MRI images, the AI-enabled software Neurophet AQUA reportedly offers quantification of lesions and structural changes associated with multiple sclerosis (MS) and volumetric brain region assessment without the need for 3D T1 images. The Neurophet AQUA software recently garnered expanded FDA 510(k) clearance for MS assessment. (Image courtesy of Adobe Stock.)
The company said key features of the AI-powered software’s MS analysis include:
• precise assessment of lesion count, volume and progression through enhanced quantification of lesions and structural changes;
• volumetric brain region assessment without the need for 3D T1 images; and
• bolstered segmentation of T2-weighted FLAIR images at 2D and 3D on 1.5T and 3T MRI platforms.
"MS is a neurological disorder that heavily relies on MRI for both diagnosis and disease monitoring, and the McDonald criteria, the diagnostic criteria for MS, specifically includes MRI confirmation of lesions disseminated in space and time," said Jake Junkil Been, the co-CEO of Neurophet. "Neurophet AQUA's advanced MS analysis technology significantly enhances efficiency and convenience for healthcare professionals, making it an indispensable tool in both diagnostic and prognostic stages."
Recent Videos
Related Content
Meta-Analysis Shows No Difference Between bpMRI and mpMRI in Ruling Out csPCa
March 6th 2025Article
In an 18-study meta-analysis involving over 4,600 patients, researchers found that bpMRI and mpMRI had equivalent pooled negative predictive value (NPV) of 92 percent for clinically significant prostate cancer (csPCa).
Is MRI Contrast Enhancement Necessary for Long-Term Monitoring of Diffuse Glioma?
March 4th 2025Article
In a comparison of contrast-enhanced T1-weighted (CET1w) MRI (and T2-weighted MRI/FLAIR imaging, researchers found that only three out of 82 cases of glioma progression were solely detected with CET1w MRI.
Can Deep Learning Ultra-Fast bpMRI Have an Impact in Prostate Cancer Imaging?
March 3rd 2025Article
A deep learning-enhanced ultra-fast bpMRI protocol offered similar sensitivity for csPCa as mpMRI with an 80 percent reduction in scan time, according to research findings presented at the European Congress of Radiology (ECR) conference.
